跳至主要内容
临床试验/NCT06160466
NCT06160466已完成不适用

Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in Follow-up Patients in a Screening Setting

Fondazione Poliambulanza Istituto Ospedaliero1 个研究点 分布在 1 个国家目标入组 1,156 人开始时间: 2020年12月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,156
试验地点
1
主要终点
Rate of patients detected with 3 or more adenomas.

研究概览

简要总结

The goal of this clinical trial is to evaluate the diagnostic yield of CADe in a consecutive population undergoing colonoscopy. The main question it aims to answer is the Adenoma Detection Rate (ADR). Participants undergoing colonoscopy for follow-up in a screening setting will be randomized in a 1:1 ratio to either receive Computer-Aided Detection (CADe) colonoscopy or a conventional colonoscopy (CC). GI Genius is the AI software that will be used in the present trial and is intended to be used as an adjunct to colonic endoscopy procedures to help endoscopists to detect in real time mucosal lesions (such as polyps and adenomas, including those with flat (non-polypoid) morphology) during standard screening and surveillance endoscopic mucosal evaluations. It is not intended to replace histopathological sampling as a means of diagnosis.Researchers will compare the CADe group and the CC-group to see if CAD-e can increase the ADR significantly.

详细描述

Even if colonoscopy is considered the reference standard for the detection of colonic neoplasia, polyps are still missed. In large administrative cohort or case-control studies, the risk of early post-colonoscopy cancer appeared to be independently predicted by a relatively low polyp/adenoma detection rate. The adenoma detection rate among different endoscopists has been shown to be strictly related with the risk of post-colonoscopy interval cancer. When considering the very high prevalence of advanced neoplasia in the FIT-positive enriched population, the risk of post-colonoscopy interval cancer due to a suboptimal quality of colonoscopy may be substantial. Available evidence justifies therefore the implementation of efforts aimed at improving adenoma detection rate, based on retraining interventions and on the adoption of innovative technologies, designed to enhance the accuracy of the endoscopic examination.Nowadays, Artificial intelligence (AI) is gaining increased attention and investigation, since it seems to improve the quality of medical diagnosis and treatment. In the field of gastrointestinal endoscopy, two potential roles of AI in colonoscopy have been examined so far: automated polyp detection (CADe) and automated polyp histology characterization (CADx). CADe can minimize the probability of missing a polyp during colonoscopy, thereby improving the adenoma detection rate (ADR) and potentially decreasing the incidence of interval cancer. GI Genius is the AI software that will be used in the present trial. The software is developed by Medtronic Inc. (Dublin, Ireland) and is intended to be used as an adjunct to colonic endoscopy procedures to help endoscopists to detect in real time mucosal lesions (such as polyps and adenomas, including those with flat (non-polypoid) morphology) during standard screening and surveillance endoscopic mucosal evaluations. It is not intended to replace histopathological sampling as a means of diagnosis.

The objective of this study was to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC). As the risk of progression is higher for large than for small adenomas the specific contribution of the new technique in reducing the miss rate of large neoplasms represents an important outcome to be assessed in the study. In addition, given the suggested association of a higher miss-rate of serrated and flat lesions with an increased risk of early post-colonoscopy CRC, the benefit of the new technique in reducing the miss rate of these lesions will be assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
50 Years 至 74 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 50 to 74 undergoing colonoscopy examination following a prior colonsocopy were polyps were found (follow-up) performed in the context of a regional mass-screening program.

排除标准

  • Patients unwilling or unable to give informed consent.
  • Patients reporting use of anti-platelet agents or anticoagulants precluding removal of polyps.

研究组 & 干预措施

Artificial intelligence arm Patients undergoing colonoscopy with artificial intelligence.

Experimental

Patients undergoing colonoscopy with artificial intelligence.

干预措施: CADe colonoscopy using GI Genius device (Device)

Conventional Colonoscopy

Active Comparator

Standard Colonoscopy with white light

干预措施: White light (Device)

结局指标

主要结局

Rate of patients detected with 3 or more adenomas.

时间窗: When available the histological report of polyps removed (up to 3 weeks).

The percentage of patients with 3 or more adenomas (serrated adenomas will also be considered in the calculation) in CADe colonoscopy group will be compared with the rate of patients with 3 or more adenomas (including serrated adenomas) in standard colonoscopy group.

Adenoma detection rate

时间窗: When available the histological report of polyps removed (up to 3 weeks).

Proportion of patients with at least one histologically confirmed adenoma resected divided by the total number of colonoscopies.

次要结局

  • Overall adenoma and polyp detection rate, flat adenoma and serrated polyps/adenomas.(When available the histological report of polyps removed (up to 3 weeks).)
  • Size of lesions detected(Immediately after the procedure.)
  • Rate of neoplasia by colonic site(Immediately after the procedure.)
  • Time of cecal intubation.(Immediately after the procedure.)
  • Withdrawal and total procedure time.(Immediately after the procedure.)
  • Specific contribution of AI(Immediately after the procedure.)
  • Post-colonoscopy surveilance(When available the histological report of polyps removed (up to 3 weeks).)
  • Learning curve.(3, 6, 9 and 12 months.)

研究者

发起方
Fondazione Poliambulanza Istituto Ospedaliero
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验